Search research articles
Contact Us
Filters
Showing results (41-50 of 116) with videos related to
Page
of 12
Sort By:
Cancer Medicine
|
July 18, 2024
Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Aasha I Hoogland, Andrew S Brohl, Brent J Small, et al.
Cells
|
September 23, 2022
Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment
Zachary J Thompson, Jamie K Teer, Jiannong Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 15, 2015
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Zeynep Eroglu, Dae Won Kim, Xiaoyan Wang, et al.
Cancer
|
September 30, 2023
Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma
Zeynep Eroglu, Y Ann Chen, Inna Smalley, et al.
Cancer Immunology, Immunotherapy : CII
|
February 12, 2026
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Tanya Ramadoss, Christian Palacios, Matthew Nichols, et al.
World Journal of Surgery
|
December 8, 2019
Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy
James Sun, Dennis A Kirichenko, Joyce L Chung, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2024
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
Tanya Ramadoss, Matthew Nichols, Christian Palacios, et al.
Cancer Medicine
|
July 20, 2024
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial
Ketty Peris, Timothy J Inocencio, Alexander J Stratigos, et al.
BMJ Open
|
May 31, 2022
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
Pashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, et al.
Journal for Immunotherapy of Cancer
|
February 28, 2017
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E Beckermann, Alpaslan Ozgun, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 116) with videos related to
Sort By:
Page
of 12
Cancer Medicine
|
July 18, 2024
Quality of life and patient-reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy
Aasha I Hoogland, Andrew S Brohl, Brent J Small, et al.
Cells
|
September 23, 2022
Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment
Zachary J Thompson, Jamie K Teer, Jiannong Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 15, 2015
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Zeynep Eroglu, Dae Won Kim, Xiaoyan Wang, et al.
Cancer
|
September 30, 2023
Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma
Zeynep Eroglu, Y Ann Chen, Inna Smalley, et al.
Cancer Immunology, Immunotherapy : CII
|
February 12, 2026
First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Tanya Ramadoss, Christian Palacios, Matthew Nichols, et al.
World Journal of Surgery
|
December 8, 2019
Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy
James Sun, Dennis A Kirichenko, Joyce L Chung, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2024
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
Tanya Ramadoss, Matthew Nichols, Christian Palacios, et al.
Cancer Medicine
|
July 20, 2024
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial
Ketty Peris, Timothy J Inocencio, Alexander J Stratigos, et al.
BMJ Open
|
May 31, 2022
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
Pashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, et al.
Journal for Immunotherapy of Cancer
|
February 28, 2017
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan, Kathryn E Beckermann, Alpaslan Ozgun, et al.
Page
of 12